209 related articles for article (PubMed ID: 29189002)
1. Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.
Zhang Y; Chen Y; Zhang D; Wang L; Lu T; Jiao Y
J Med Chem; 2018 Jan; 61(1):140-157. PubMed ID: 29189002
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
5. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity.
Mahmoud HK; Farghaly TA; Abdulwahab HG; Al-Qurashi NT; Shaaban MR
Eur J Med Chem; 2020 Dec; 208():112752. PubMed ID: 32947227
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
[TBL] [Abstract][Full Text] [Related]
7. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.
Ahmed MF; Santali EY; El-Haggar R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069
[TBL] [Abstract][Full Text] [Related]
8. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
9. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM
Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
[TBL] [Abstract][Full Text] [Related]
19. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.
Abou-Seri SM; Eldehna WM; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 Jan; 107():165-79. PubMed ID: 26590508
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB
Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
